so subgroup analysis for gilead breast cancer drug
Post# of 148140
(Total Views: 615)
Posted On: 09/12/2022 8:16:32 PM
so subgroup analysis for gilead breast cancer drug that extended survival by a few months = ok and downright exciting
subgroup analysis of cytodyn covid paitents during an emergency that had 78% and 84% SURVIVAL RATES over placebo + standard treatment = not ok and downright obnoxious to even consider subgroups
got it.
so glad the FDA is our guardian. i feel so safe now.
when will these pastey clowns get challenged? why is their power so absolute?
subgroup analysis of cytodyn covid paitents during an emergency that had 78% and 84% SURVIVAL RATES over placebo + standard treatment = not ok and downright obnoxious to even consider subgroups
got it.
so glad the FDA is our guardian. i feel so safe now.
when will these pastey clowns get challenged? why is their power so absolute?
(17)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼